A prospective, single-center study to evaluate the clinical performance of Meril ABFind in individuals vaccinated against COVID-19

1 Jayanthi Shastri¹*, Sachee Agrawal¹, Nirjhar Chatterjee¹, Harsha Gupta¹

- ² ¹Kasturba Hospital for Infectious Diseases, Mumbai, India.
- 3 *** Correspondence:**
- 4 Dr. Jayanthi S. Shastri
- 5 Head, Molecular Diagnostic Reference Laboratory
- 6 Kasturba Hospital for Infectious Diseases,
- 7 Mumbai-400034, Maharashtra, India.
- 8 E-mail: jsshastri@gmail.com
- 9 Number of words: 3457
- 10 Number of Tables: 5
- 11 Number of Figures: 1

12 Abstract

13 Background: Accurate rapid antibody detection kits requiring minimum infrastructure are beneficial

- 14 in detecting post-vaccination antibodies in large populations. ChAdOx1-nCOV (COVISHIELD[™])
- 15 and BBV-152 (CovaxinTM) vaccines are primarily used in India.

Methods: In this single-centre prospective study, performance of Meril ABFind was investigated by comparing with Abbott SARS-CoV-2 IgG II Quant (Abbott Quant), GenScript cPass SARS-CoV-2 neutralization antibody detection kit (GenScript cPass), and COVID Kawach MERILISA (MERILISA) in 62 vaccinated health care workers (HCW) and 40 pre-pandemic samples.

Results: In the vaccinated subjects, Meril ABFind kit displayed high sensitivity of 93.3% (CI, 89.83%-96.77%), 94.92% (CI, 91.88%-97.96%), and 90.3% (CI, 86.20%-94.4%) in comparison to Abbott Quant, MERILISA, and GenScript cPass respectively. The results of the Meril ABFind in the COVISHIELD-vaccinated group were excellent with 100% sensitivity in comparison to the other three kits. In the Covaxin-vaccinated group, Meril ABFind displayed sensitivity ranging from 80% to 88.9%. In control samples, there were no false positives detected by Meril ABFind, while Abbott

- 26 Quant, MERILISA, and GenScript cPass reported 2.5%, 10.0%, and 12.5% false positives,
- 27 respectively. In the pre-pandemic controls, specificity of Meril ABFind was 100%, Abbott Quant
- 28 97.5%, MERILISA 90%, and GenScript cPass 87.5%.
- 29 *Conclusion:* The Meril ABFind kit demonstrated satisfactory performance when compared with the 30 three commercially available kits and was the only kit without false positives in the pre-pandemic
- 31 samples. This makes it a viable option for rapid diagnosis of post vaccination antibodies.

32 **Keywords:** SARS-CoV-2, COVID-19, adaptive immunity, humoral immunity, neutralizing 33 antibodies, rapid test.

34 **1 Introduction**

35 SARS-CoV-2 which belongs to Betacoronavirus genus and Coronaviridae family is the causative 36 agent for COVID-19. The spike protein (S-glycoprotein) present on the surface of the virus has a 37 receptor binding domain (RBD) which binds to the angiotensin-converting enzyme 2 (ACE2) present 38 on the cell surfaces and mediates the entry of this virus inside the host cell (1). Within the first three 39 weeks of getting infected with the virus, the patients develop antibodies against the RBD of the viral 40 spike protein (2). Early development of antibodies is important for survival and control of infection 41 in the patients. These neutralizing antibodies provide protection from future infection by interfering 42 with the interaction between the virus's spike RBD and host's ACE2.

43 India has primarily used ChAdOx1-nCOV (COVISHIELDTM) and BBV-152 (CovaxinTM) vaccines 44 with health care workers (HCW) being the first group to get vaccinated. Serological tests can detect 45 the humoral immune response following past infection and vaccination, and they can be useful for 46 serological studies. Serology has also been used to make clinical decision on therapeutic 47 interventions (3). While accurate laboratory based serological assays are available in India, a large 48 rural population mandates reliable serological assays to detect humoral immunity following 49 vaccination and post infection which can be performed without expensive laboratory equipment and 50 cumbersome techniques. To address this unmet need, several companies are working on the 51 development of reliable antibody testing kits with adequate sensitivity and specificity (4). Different 52 diagnostic kits are available to identify individuals with immune response after the vaccine 53 administration. Testing a huge number of vaccinated individuals with a diagnostic assay which 54 requires complicated instruments and infrastructure would be cumbersome and would not be 55 economical. In the given situation, a rapid test would be advantageous owing to speed of 56 performance, quick results and minor requirements of equipments and infrastructure.

57 The Meril ABFind kit (Meril Diagnostics Pvt. Ltd., India) can detect circulating SARS-CoV-2 58 neutralizing antibodies that block the interaction between the RBD of the viral spike glycoprotein and 59 the ACE2 cell surface receptor in serum, plasma and whole blood. This study was designed to 60 investigate the clinical performance of this rapid antibody testing kit by evaluating its diagnostic sensitivity and specificity for the qualitative detection of neutralizing antibodies in defined and 61 characterized specimens. For evaluating the performance of this kit, the results obtained were 62 63 compared with the results obtained using three other commercially available kits viz. Abbott SARS-64 CoV-2 IgG II Quant (Abbott Diagnostic, USA), GenScript cPass SARS-CoV-2 neutralization antibody detection Kit (GenScript, USA), and COVID Kawach MERILISA (Meril Diagnostic, Pvt. 65 66 Ltd., India).

67 2 Materials & Methods

68 2.1 Study Participants

A total of 62 participants of which 32 had been vaccinated with COVISHIELD and 30 with Covaxin, 69 70 were recruited for this study in the months of June, July and August 2021. All recruited participants 71 were health care workers working in the city of Mumbai, India. The inclusion criteria for the study 72 were: healthcare workers in the age range of 18 to 60 years, fully vaccinated, i.e., two weeks after the 73 second dose of COVISHIELD or Covaxin and less than 12 weeks after the second dose of 74 COVISHIELD or Covaxin. Any individual who reported symptoms suggestive of COVID-19 were to 75 be excluded, however none of the participants showed any such symptoms. The study was approved 76 by the Institutional Review Board of Kasturba Hospital of Infectious Diseases, Mumbai, India; IRB number 05/2021. Written informed consent was obtained from all study participants. All collection, 77 78 processing of samples and archiving of results were performed under approval from the Institutional 79 Review Board.

The baseline demographics and the medical history of the participants were collected for analysis andevaluation.

82 2.2 Sample collection:

One 5 ml vial of blood was collected by venipuncture from the cubital vein in serum separator tubes.
Separated plasma was used for testing in all four tests. 40 stored pre-pandemic samples were used as
a known negative control. These samples were collected in 2018 from patients with an acute febrile
illness. Plasma was separated and stored at -80 °C in our laboratory (Molecular Laboratory, Kasturba
Hospital for Infectious Diseases, Mumbai, India).

88 2.3 Serological Tests

All the samples were tested first using Abbott SARS-CoV-2 IgG II Quant (Abbott Quant). Then the
samples were tested using the Meril ABFind kit and the two commercially available kits, COVID
Kawach MERILISA (MERILISA) and GenScript cPass SARS-CoV-2 neutralization antibody
detection kit (GenScript cPass).

93 The Abbott Quant kit results were beneficial in comparing anti-RBG IgG in the COVISHIELD- and 94 Covaxin-vaccinated subjects in a quantitative manner. Meril ABFind kit is a qualitative membrane-95 based immunoassay for the detection of SARS-CoV-2 neutralizing antibody in whole blood, serum 96 or plasma. This detection kit utilizes a colloidal gold labeled SARS-CoV-2 recombinant Receptor 97 Binding Domain (rRBD) which binds with the SARS-CoV-2 neutralizing antibody of IgG class if 98 present in the sample to give a colored band. A control band must be present for the test to be 99 considered valid. A control band and a test band was considered positive, a control band without a 100 test band was considered negative and absence of the control band was considered invalid 101 irrespective of the test band. The test specimen was diluted in 1:10 ratio with sample dilution buffer 102 and was added on the membrane strip, the results were read at the end of 20 minutes.

103 The Abbott SARS-CoV-2 IgG II Quant assay is a two-step automated chemi-luminescent 104 microparticle immunoassay (CMIA) intended for the qualitative and quantitative determination of 105 IgG antibodies to the RBD of the spike protein of SARS-CoV-2 in human serum and plasma. The 106 analytical measurement interval was stated as 21 to 40,000 AU/ml, and positivity cut off was 107 \geq 50 AU/ml (defined by manufacturer) (5).

- 108 GenScript cPass SARS-CoV-2 neutralization antibody detection kit is a blocking ELISA detection
- 109 tool which mimics the virus neutralization process. It uses horseradish peroxidase (HRP) conjugated
- 110 recombinant RBD protein and human angiotensin converting enzyme-2 (ACE-2) receptor protein.
- 111 The protein interaction between HRP-RBD and ACE-2 can be blocked by neutralizing antibodies
- 112 against SARS-CoV-2 RBD. Signal inhibition was calculated as follow:
- Percent Signal Inhibition = (1- average optical density value of sample/average optical density value of negative control) × 100%
- 115 The test results were interpreted as positive when the percent signal inhibition was \geq 30%, which was
- 116 the cut-off for signal inhibition claimed by the manufacturer (6).
- 117 Covid Kawach MERILISA is an immune assay based on indirect enzyme linked immunosorbent
- 118 assay principle for qualitative detection of IgG antibodies against SARS-CoV-2 in the sample. The
- 119 optical density (OD) of the plate is read at 450 nm. This kit comes with a positive and negative
- 120 control which works as marker of the kit. P/N ratio of positive control is defined as ratio of OD value
- 121 of positive control to the average of the ODs of negative control. The test is considered to be valid if
- 122 P/N ratio of positive control is greater than 1.5.
- 123 Cut off calculations = Average negative control + 0.2

For the test sample, if OD value was greater than the cut-off value and P/N ratio was more than 1.5, sample was considered positive. While, for the test sample, if OD value was less than the cut-off value and P/N ratio was less than 1.5, sample was considered negative (7).

127 2.4 Managing Test Results

Results of all four tests were given to participants with the understanding that testing was done in the context of a research study. No clinical decisions were made on the basis of this study. Participants were informed that a positive result did not preclude COVID-19 in the future and that a negative result did not necessarily mean lack of protection against COVID-19.

132 2.5 Statistical analysis

133 Continuous variables like age were summarized with mean±SD, and categorical variables like gender 134 were presented with count (%). Primary analyses, to evaluate diagnostic accuracy of the 135 investigational kit, were reported with % for sensitivity and specificity. 95% confidence interval is 136 specified for sensitivity and specificity. Positive predictive value specifies the proportions of true 137 positive and negative predictive value species the proportions of true negative. In the vaccinated 138 groups, true positives are the samples that tested positive using the study kit and the comparator kit 139 and true negatives are the samples that tested negative using the study kit and the comparator kit. If 140 the sample test positive with the gold standard but negative with the investigational kit, it was considered as false negative. If the sample test negative with the gold standard but positive with the 141 142 investigational kit, it was considered as false positive. For pre-pandemic control samples, all the 143 samples were considered as true negative as the samples were collected in 2018 before the emergence 144 of SARS-CoV-2 and therefore antibodies against SARS-CoV-2 could not be present in these 145 samples. So, in this group, any positives detected were considered as false positive and all negatives 146 reported were considered true negatives. Sensitivity and specificity were calculated using the 147 formulae:

- 148 Sensitivity: (True positive)/(True positive + False negative)
- 149 Specificity: (True negative)/(True negative + False positive) (6)

150 **3 Results**

Demographic data of the subjects in the vaccinated group (n=62) are presented in Table 1. The samples were collected at a median 62 (16-84) days after the second dose of vaccination in the cohort of the total vaccinated population. The mean age of this population was 36.5 ± 11.58 years; of which 43.75% were male and 56.25% were female. Among this population, presence of comorbidities such as hypertension, heart disease, and diabetes were 6.45%, 1.61%, and 4.84%, respectively. Demographic details and co-morbidities for the COVISHIELD- and Covaxinvaccinated groups are presented separately in Table 1.

For further clarity, we performed individual analysis of all four kits for both the vaccinated groups separately (Table 2). Analyses of Meril ABFind kit versus the other three kits as gold standard in the combined vaccinated cohort, COVISHIELD-vaccinated group and Covaxin-vaccinated group are shown in Table 3. In the combined vaccinated population, the Meril ABFind kit displayed 93.3% (CI, 89.83%-96.77%), 94.92% (CI, 91.88%-97.96%), and 90.3% (CI, 86.20%-94.4%) sensitivity in comparison to Abbott Quant, MERILISA, and GenScript cPass, respectively.

164 In the COVISHIELD-vaccinated group, the results obtained with Meril ABFind kit were compared 165 to the results obtained with other three kits considering them as "gold standard". Samples from all 166 the COVISHIELD receptents were positive by all four tests kits. The sensitivity of Meril ABFind kit 167 in comparison to all the other three kits in this group was 100%. The positive predictive value 168 calculated for Meril ABFind kit versus other three kits was also observed to be 100% In the 169 Covaxin-vaccinated group, Meril ABFind kit displayed 85.7% (CI, 71.79%-99.71%), 88.9% (CI, 170 76.33%-100%), and 80% (CI, 64%-96%) sensitivity in comparison to Abbott Quant, MERILISA, 171 and GenScript cPass, respectively. The specificity of the Meril ABFind kit in comparison to all the 172 three kits was 100%.

The 40 pre-pandemic control samples tested with these four different kits showed different positive and negative results (Table 4). In the pre-pandemic controls, the Meril ABFind kit did not produce any false positive results. However, all the other three kits, Abbott Quant, MERILISA, and GenScript cPass did produce false positive results; 1, 4 and 5 false positives each, respectively. In this group, the specificity of Meril ABFind kit, Abbott Quant, MERILISA, and GenScript cPass

178 were reported to be 100%, 97.5%, 90%, and 87.5% respectively.

179 Quantitative antibody responses were significantly higher (p=0.01) after COVISHIELD vaccination

- 180 (2889.36 \pm 3572 AU/mL; CI 1651.72 to 4127) versus Covaxin vaccination (1054.13 \pm 1360.01
- 181 AU/mL; CI 582.90 to 1525.35) detected by the Abbott Quant kit (Table 5).

182 **4 Discussion**

Previous studies have shown that neutralizing antibodies are targeted against spike protein, specifically the RBD and N-terminal domain of SARS-CoV-2 (8-10). Of monoclonal antibodies isolated from SARS-CoV-2 infected individuals, almost all those which potently neutralized SARS-CoV-2 *in vitro* were against RBD and a few against N-terminal domain (11).

187 Meril ABFind kit is based on detection of IgG antibodies against RBD in the specimens. This study 188 evaluated the sensitivity and specificity of Meril ABFind kit in detecting COVID-19 antibodies in 189 the samples collected from a diverse population. In this study, we had two groups of samples, one 190 from COVID-19 vaccinated (either with COVISHIELD or Covaxin) group and the other from a pre-191 pandemic control group. The vaccinated group was further divided into a COVISHIELD-vaccinated 192 group and a Covaxin-vaccinated group. The two vaccinated groups were comparable in terms of age 193 and presence of pre-existing medical conditions (diabetes, hypertension, heart disease). The timing 194 of sample collection from the second dose was also comparable in both the vaccinated groups.

195 The manufacturer claimed sensitivity and specificity of Abbott Quant were 99.35% and 99.6% (12), 196 Covid Kawach MERILISA were approximately 93% and 100% (7) and GenScript cPass were 197 93.80% and 99.40%, respectively (13). Previous studies have also reported the sensitivity and 198 specificity of the comparator kits. In one study, Abbott Quant kit demonstrated 96% sensitivity and 199 99.3% specificity in comparison to GenScript cPass (6). The Abbott Quant kit was also used in 200 investigating the anti-spike IgG responses in health care workers following one or two doses of 201 Pfizer-BioNTech or Oxford-Astrazenca vaccines (14). The GenScript cPass SARS-CoV-2 202 neutralization antibody detection kit is the first commercially available kit to detect neutralizing 203 antibodies against SARS-CoV-2 RBD. One of the initial studies with this kit reported the sensitivity 204 and specificity of this kit in the range of 77-100% and 95-100%, respectively, in comparison to 205 plaque-reduction neutralization test and pseudo typed lentiviral neutralization assay (15). For our 206 study, we have compared the performance of Meril ABFind kit with the other three commercially 207 available kits and have not performed comparative analysis amongst the comparator kits. However, 208 from the number of positive and negative cases detected, it can be inferred that the performance of all 209 the kits used in this study were not identical.

The performance of the Meril ABFind kit was evaluated by comparing with the performance of the comparator kits viz. Abbott Quant, MERILISA, and GenScript cPass in both the groups. In the vaccinated population, the Meril ABFind kit displayed sensitivity of over 90% with all three comparators; 93.3% (CI, 89.83%-96.77%) with Abbott Quant, 94.92% (CI, 91.88%-97.96%) with MERILISA, and 90.3% (CI, 86.20%-94.4%) with GenScript cPass.

In the COVISHIELD-vaccinated group, in comparison to the other three kits the Meril ABFind kit displayed 100% sensitivity. As all the four kits have reported positive results and there were no negatives reported by any of them, calculating specificity of the kits was not valid for this group.

218 In the Covaxin-vaccinated group, the Meril ABFind kit had a sensitivity of 85.7% (CI, 71.79%-

219 99.71%) with Abbott Quant, 88.9% (CI, 76.33%-100%) with MERILISA, and 80% (CI, 64%-96%)

220 with GenScript cPass. The specificity was 100% against all three comparator tests.

A study in India comparing anti-Spike antibody responses following COVISHIELD and Covaxin found that seropositivity and geometric mean titers were higher following COVISHIELD vaccination compared to Covaxin vaccination (16). In our study, a significantly higher (p=0.01) level of anti-RBD IgG antibodies were detected in the COVISHIELD-vaccinated group versus the Covaxin-vaccinated group by the Abbott Quant kit. This may explain why Meril ABFind had a

better sensitivity in the COVISHIELD group compared to the Covaxin group. Additionally, Meril
ABFind does not detect antibodies against non-RBD epitopes. Covaxin is a whole virus inactivated
vaccine and generates antibody responses against Spike and non-Spike antigens, while Meril
ABFind only detects antibodies against the RBD. However, our study was not designed to compare
the seropositivity between COVISHIELD- and Covaxin-vaccinated individuals. Based on our study,
we cannot comment on the immunogenicity or efficacy of COVISHIELD compared with Covaxin.

The control samples were collected before the pandemic, and in this group the results of all four kits differed. It was deemed impossible for these samples to contain antibodies against specific SARS-CoV-2 antigens as these samples were collected in 2018. Any positives in these samples would necessarily be false positives due to cross reactivity with antibodies against other endemic coronaviruses or other non-coronavirus pathogens. These samples were collected from patients with an acute febrile illness which included dengue and leptospirosis but may have also included other infectious diseases which may have resulted in cross reactivity and false positives.

In the pre-pandemic control samples, all positive results by Abbott Quant, MERILISA, and GenScript cPass were classified as false positive results as it was not possible for these samples to contain antibodies against SARS-CoV-2. The Meril ABFind kit did not produce a single false positive in the pre-pandemic controls, and therefore in this cohort, Meril ABFind kit was 100% specific, which was better than Abbott Quant IgG II, MERILISA, and GenScript cPass (Figure 1).

244 Interestingly, Abbott Ouant, MERILISA, and GenScript cPass detected 2.5%, 10%, and 12.5% false 245 positives, respectively. As all three of these kits (Abbott Quant, MERILISA, and GenScript cPass kits) produced false-positive results in the pre-pandemic samples, it is possible that they produced 246 247 some false positives in the samples from the Covaxin-vaccinated subjects as well. It is possible that 248 Meril ABFind displayed a higher sensitivity in the Covaxin group while the comparator kits (Abbott 249 Quant, MERILISA, and GenScript cPass) displayed specificity lower than reported in literature. It 250 would be prudent to assess these assays in a large cohort of pre-pandemic samples from India to 251 ensure absence of cross-reactivity against non-SARS-CoV-2 coronaviruses or other pathogens.

252 Currently, many diagnostic kits which were developed to detect antibodies against SARS-CoV-2 in 253 specimens collected from infected and vaccinated individuals against COVID-19 are commercially 254 available. The rapid lateral flow serological assays were the first commercially available serological 255 assays, but their poor sensitivity and specificity made them unsuitable for use (11). Since then 256 numerous laboratory-based assays, for example CLIA & ELISA have been introduced in India with 257 reported high sensitivity and specificity. However, there is a lack of laboratory infrastructure, 258 technical expertise in rural India for such assays. Serological assays have demonstrated great value 259 in serological studies to understand the percentage of the population that has COVID-19 antibodies. Such studies will continue to be relevant in the future. Serology has also been used to guide clinical 260 261 decision making. In the UK, NHS guidelines recommend offering a combination of casirivimab and 262 imdevimab to people aged 12 and over in hospital with COVID-19 who have no detectable SARS-263 CoV-2 antibodies (seronegative) (3). This treatment works best when administered early in disease 264 course and accurate point of care serological tests may offer value in this setting. While serology is 265 not currently used to guide decisions on vaccination, it is possible that in the future decisions on the 266 need for additional doses of COVID-19 vaccines or boosters will be based on serology. Therefore, 267 an accurate point of care serological test may offer value in future serological studies, clinical 268 decision making and vaccination programs. A rapid and accurate serological assay that can detect post vaccination COVID-19 neutralizing antibodies would be especially useful in areas where 269 270 laboratory facilities are not available.

271 In this study, the Meril ABFind kit showed excellent sensitivity and specificity in the

272 COVISHIELD- and Covaxin-vaccinated groups. Notably, Meril ABFind kit was the only assay in 273 this study that had a zero false positivity rate and 100% specificity in the pre-pandemic samples, 274 while all three comparator kits had some false positives. This suggests the conventional thought 275 process that rapid point of care tests are necessarily less accurate or specific than laboratory based 276 assays may not always hold true, at least as concerns SARS-CoV-2 serological tests.

277 Our study also highlights the need to investigate laboratory based assays for cross reactivity in the 278 Indian population. If we had not used pre-pandemic samples as a control, we would have missed the 279 possibility that Abbott Quant, MERILISA, and GenScript cPass had a false positivity rate as high as 280 2.5%, 10% and 12.5%. While it is important to have sensitive assays that can correctly detect all 281 individuals who have an adaptive humoral response to SARS-CoV-2, it is equally important to 282 ensure that an assay is specific and doesn't incorrectly label those who do not have antibodies as 283 being sero-positive, particularly for neutralizing antibodies against SARS-COV-2. False positive 284 results in serological studies may result in over-estimating the population that has antibodies from 285 infection and vaccination, and this may have important implications on policy decisions. A false 286 positive result may disgualify an individual from a therapeutic like a monoclonal antibody cocktail 287 when it is dependant on serological status.

288 Our study shows that point of care serological tests can be a suitable alternative to laboratory based 289 assays. Meril ABFind kit has an excellent sensitivity and specificity in comparison to commercially 290 available laboratory assays and holds promise in accurate identification of SARS-CoV-2 anti-RBD 291 neutralizing antibodies. In our study, Meril ABFind kit was the only assay that didn't produce false 292 positives. The results of the control pre-pandemic samples show that the Meril ABFind kit had the 293 highest specificity in pre-pandemic control samples. However, larger studies with larger sample size 294 are warranted to provide conclusive evidence of comparative performance of all the kits used in this 295 study.

296 **5** Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

299 6 Author Contributions

JS conceptualized the study. SA, NC and HG collected and compiled data. JS, SA, NC and HG
 drafted the manuscript, prepared tables and figures. All authors contributed to data interpretation,
 writing, critically reviewing, revising, and approving the final manuscript for submission.

303 **7 Funding**

This work was supported by the Municipal Corporation of Greater Mumbai's funding for Kasturba
 Hospital's COVID-19 diagnostic laboratory. GenScript cPass SARS-CoV-2 neutralization antibody
 detection kits, COVID Kawach MERILISA kits and Meril ABFind kits were provided by Meril
 Diagnostic Pvt Limited.

308 8 Acknowledgments

- 309 The authors acknowledge and thank the Municipal Corporation of Greater Mumbai for their support
- through the study. We thank Meril Diagnostic Pvt. Limited for providing test kits to conduct the
- 311 study. We thank the health workers who participated in this study.

312 9 Data Availability Statement

- 313 The original contributions presented in the study are included in the article. Further inquiries can be
- 314 directed to the corresponding author.

315 **10 References**

Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, *et al.* Author Correction:
 Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. *Nat Commun* (2021) 12:2996. doi: 10.1038/s41467-020-18319-6.

Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, *et al.* Neutralizing
 antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
 Nat Commun (2021) 12:2670. doi: 10.1038/s41467-021-22958-8.

- 322 3. National Institute of Health and Care Excellence. (2021).
 323 https://www.nice.org.uk/guidance/ng191/chapter/Recommendations [Accessed November 11, 2021].
- 324 4. Petherick A. Developing antibody tests for SARS-CoV-2. *Lancet* (2020) 395:1101-2. doi:
 325 10.1016/S0140-6736(20)30788-1.

5. English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG. Performance of the Abbott
SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC
202012/V1 (United Kingdom) and VOC 202012/V2 (South Africa), and First Steps towards Global
Harmonization of COVID-19 Antibody Methods. *J clin microbiol* (2021) 59:e0028821. doi:
10.1128/JCM.00288-21.

Jung K, Shin S, Nam M, Hong YJ, Roh EY, Park KU, *et al.* Performance evaluation of three
automated quantitative immunoassays and their correlation with a surrogate virus neutralization test
in coronavirus disease 19 patients and pre-pandemic controls. *J clin lab anal* (2021) 35:e23921. doi:
10.1002/jcla.23921.

3357.MerilLifeSciencesPvt.Ltd.(2021).https://www.merillife.com/medical-336devices/diagnostics/covid-19/immunology/covid-kavach-merilisa[Accessed November 11, 2021].

Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, *et al.* A SARS-CoV Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. *Cell* (2020)
 182:744-53.e4. doi: 10.1016/j.cell.2020.06.011

340• 9. Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.
341 *Antib Ther* (2020) 3:109-14. doi: 10.1093/abt/tbaa009.

- Huang Y, Sun H, Yu H, Li S, Zheng Q, Xia N. Neutralizing antibodies against SARS-CoV-2:
 current understanding, challenge and perspective. *Antib Ther* (2020) 3:285-99. doi:
 10.1093/abt/tbaa028.
- Meschi S, Colavita F, Bordi L, Matusali G, Lapa D, Amendola A, *et al.* Performance
 evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect
 immunofluorescence and virus microneutralization test. *J clin virol* (2020) 129:104539. doi:
 10.1016/j.jcv.2020.104539.
- Abbott. (2021). https://abbott.mediaroom.com/2020-12-15-Abbott-Receives-CE-Mark-for-its COVID-19-IgG-Quantitative-Antibody-Blood-Test [Accessed on November 13, 2021].
- 351 13. GenScript. (2021). *https://www.genscript.com/covid-19-detection-ce.html* [Accessed on
 352 November 13, 2021].

Eyre DW, Lumley SF, Wei J, Cox S, James T, Justice A, *et al.* Quantitative SARS-CoV-2
anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection
status. *Clin microbiol infect* (2021) 27:1516.e7-.e14. doi: 10.1016/j.cmi.2021.05.041.

15. Papenburg J, Cheng MP, Corsini R, Caya C, Mendoza E, Manguiat K, *et al.* Evaluation of a
Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory
Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain EnzymeLinked Immunosorbent Assay. *Open forum infect dis* (2021) 8:ofab220. doi: 10.1093/ofid/ofab220.

360 Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, et al. Antibody 16. 361 response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus 362 antibody titre study. 363 vaccine-induced (COVAT) Vaccine (2021)39:6492-509. doi:

364 10.1016/j.vaccine.2021.09.055

366	Table legends:
500	I ubic regenus.

- **Table 1:** Demographic details of the participants
- **Table 2:** Performance of different antibody detecting kits in COVISHIELD-vaccinated group and
- 369 Covaxin-vaccinated group
- Table 3: Analysis of Meril ABFind kit versus the other three kits as gold standard in the combined
 vaccinated cohort, COVISHIELD-vaccinated group and Covaxin-vaccinated group
- **Table 4:** Performance of different antibody detecting kits in pre-pandemic control samples
- Table 5: Quantitative determination of SARS-CoV -2 antibodies in COVISHIELD -vaccinated and
 Covaxin-vaccinated group by Abbott Quant

378 Figure Legends:

- **Figure 1:** Specificity of the four kits in the pre-pandemic control group

Table 1:	Demographic	details of	the	particii	oants
I abic I.	Demographic	uctums of	unc	pui uci	Juiius

Characteristics	Combined vaccinated cohort	COVISHIELD -vaccinated group	Covaxin-vaccinated group					
Age	36.65±11.58	36.56±12.20	36.73±11.09					
Gender	Gender							
Male	21(43.75)	14 (43.75)	7 (23.33)					
Female	41(56.25)	18 (56.25)	23 (76.67)					
Time span between	Time span between 2nd dose of vaccine and blood collection (Days)							
Average (Mean±SD)	58.45±19.61	62.33±21.62	55.46±17.63					
Median (Min,Max) 62(16,84)		70 (16, 84)	58 (22, 83)					
Comorbidity, n(%)								
Hypertension	4(6.45)	2(6.25)	2(6.67)					
heart disease	1(1.61)	1(3.13)	0 (0)					
Diabetes 3(4.84)		1(3.13)	2(6.67)					

Table 2: Performance of different antibody detecting kits in COVISHIELD -vaccinated group and Covaxin-vaccinated group

	COVISHIELD-vaccinated group			Covaxin-vaccinated group			oup	
Results	Meril ABFind (n=32)	Abbott IgG II (n=32)	MERILIS A (n=32)	GenScript (n=32)	Meril ABFind (n=30)	Abbott IgG II (AU/mL) (n=30)	MERILIS A (n=30)	GenScript (n=30)
Positive	32	32	32	32	24	28	27	30
Negative	0	0	0	0	6	2	3	0

398 (Abbott IgG II, Abbott SARS-CoV-2 IgG II Quant; GenScript, GenScript cPass SARS-CoV-2

399 neutralization antibody detection Kit; MERILISA, Covid Kawach MERILISA)

Table 3: Analysis of Meril ABFind kit versus the other three kits as gold standard in the combined vaccinated cohort, COVISHIELD-vaccinated group and Covaxin-vaccinated group

	Combined vaccinated cohort			COVISHIELD-vaccinated group			Covaxin-vaccinated group		
Parameters	Meril ABFind vs Abbott IgG II	Meril ABFind vs MERILISA	Meril ABFind vs GenScrip t	Meril ABFind vs Abbott IgG II	Meril ABFind vs MERILI SA	Meril ABFind vs GenScrip t	Meril ABFind vs Abbott IgG II	Meril ABFind vs MERILI SA	Meril ABFind vs GenScrip t
Sensitivity	93.3%	94.92%	90.3%	100%	100%	100%	85.7%	88.9%	80%
Specificity	100%	100%	NA	NA	NA	NA	100%	100%	NA
Positive predictive value	100%	100%	100%	100%	100%	100%	100%	100%	NA
Negative predictive value	33.3%	50%	NA	NA	NA	NA	100%	100%	100%
Confidence Interval for Sensitivity	89.83% to 96.77%	91.88% to 97.96%	86.20% to 94.40%	NA	NA	NA	71.71 to 99.71	76.33 to 100.00	64.00 to 96.00

403 (Abbott IgG II, Abbott SARS-CoV-2 IgG II Quant; GenScript, GenScript cPass SARS-CoV-2

404 neutralization antibody detection Kit; MERILISA, Covid Kawach MERILISA)

406	Table 4: Performance of different antibody	v detecting kits in	pre-pandemic control samples
-----	--	---------------------	------------------------------

Results, n(%)	Meril ABFind (N=40)	Abbott IgG II (N=40)	MERILISA (N=40)	GenScript (N=40)
Specificity	40(100%)	39(97.5%)	36(90%)	35(87.5%)
False positive	0	1(2.5%)	4(10%)	5(12.5%)

407 (Abbott IgG II, Abbott SARS-CoV-2 IgG II Quant; GenScript, GenScript cPass SARS-CoV-2
 408 neutralization antibody detection Kit; MERILISA, Covid Kawach MERILISA)

409

410

412 Table 5: Quantitative determination of SARS-CoV-2 antibodies in COVISHIELD-vaccinated 413 and Covaxin-vaccinated group by Abbott Quant

	Abbott Qua	p-value	
Vaccines	COVISHIELD- vaccinated (n=32)	Covaxin-vaccinated (n=30)	
Mean ± SD	2889.36 ± 3571.99	1054.13 ± 1360.01	0.010
95% CI	1651.72 to 4126.99	582.90 to 1525.35	
Min, Max	83.4, 13611.7	11.9, 5632.1	



414 415

Figure 1: Specificity of the four kits in the pre-pandemic control group